Clinical trials: Phase I
Healthy
Study of Single and Multiple Ascending Doses of PF-07059013 in Healthy Adult Participants
The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) of single and multiple ascending oral doses of PF-07059013 in healthy adult participants.
- Trial name
- NCT04323124
- Testing
- PF-07059013
- Where
- Belgium
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Pfizer
Advanced Colorectal Carcinoma
A Dose Escalation Study of APR003 in Patients With Advanced Colorectal Cancer (CRC) With Malignant Liver Lesions
A Phase 1 dose escalation study to evaluate APR003 in patients with advanced colorectal cancer (CRC) with malignant liver lesions
- Trial name
- NCT04645797
- Testing
- APR003
- Where
- 4 sites in United States
- Volunteers
- 11 people
- Sponsor
- Apros Therapeutics, Inc
Glioblastoma Multiforme
Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme
In this phase I/II study,investigators are evaluating the feasibility and efficacy of the combination of BKM120, an oral inhibitor of PI3 kinase, and bevacizumab in the treatment of patients with relapsed/refractory GBM.
- Trial name
- NCT01349660
- Testing
- Bevacizumab, BKM120
- Where
- 8 sites in United States
- Volunteers
- 88 people
- Sponsor
- SCRI Development Innovations, LLC
Pneumonia, Bacterial
Urease Breath Test for Rapid Characterization of Pneumonia
This is a Phase 1, open label, evaluation of a 13C-urea breath test for the detection of urease-producing bacteria in patient with pneumonia in the emergency department.
- Trial name
- NCT03100760
- Testing
- 13C-urea breath test
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of New Mexico
Cervical Cancer
A Study of Zalifrelimab and Balstilimab for Treatment of Participants With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical)
This is a Phase 1/2, open-label study of zalifrelimab (AGEN1884) in combination with balstilimab (AGEN2034) in participants with locally advanced, recurrent and/or metastatic solid tumors including cervical cancer.
- Trial name
- NCT03495882
- Testing
- Zalifrelimab, Balstilimab
- Where
- 47 sites in United States, Australia and 7 more
- Volunteers
- 175 people
- Sponsor
- Agenus Inc.
Refractory Multiple Myeloma, Smoldering Multiple Myeloma
Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma
RATIONALE: Melphalan, a chemotherapeutic agent, has been found to be an effective treatment choice for destroying myeloma cells, especially when given at high (bone marrow ablative) doses.
- Conditions
- Refractory Multiple Myeloma, Smoldering Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma
- Trial name
- NCT00112827
- Testing
- total marrow irradiation, melphalan, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- City of Hope Medical Center
Inoperable Locally Advanced or Metastatic Biliary Tract Cancer
Selumetinib (AZD6244, ARRY-142886) J-BTC Phase 1 Study
The objective of this study is to investigate the safety and tolerability of oral dose of selumetinib in combination with chemotherapies (cisplatin and gemcitabine) in Japanese patients with advanced biliary tract cancer (BTC).
- Trial name
- NCT01949870
- Testing
- Cisplatin, Gemcitabine, Selumetinib
- Where
- 2 sites in Japan
- Volunteers
- 6 people
- Sponsor
- AstraZeneca
Influenza Infection
Dose, Safety, Tolerability and Immunogenicity of an Influenza H1 Stabilized Stem Ferritin Vaccine in Healthy Adults
Background: The flu is a common viral infection that can be deadly for certain people. Vaccines against flu have been developed to teach the body to prevent or fight the infection.
- Trial name
- NCT03814720
- Testing
- VRC-FLUNPF099-00-VP (H1ssF_3928)
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Small Cell Lung Carcinoma
A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)
This randomized, Phase I/III, multicenter, double-blinded, placebo-controlled study was designed to evaluate the safety and efficacy of atezolizumab (anti-programmed death-ligand 1 [PD-L1] antibody) in combination with…
- Trial name
- IMpower133 (NCT02763579)
- Testing
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Carboplatin, Etoposide
- Where
- 114 sites in United States, Australia and 19 more
- Volunteers
- 503 people
- Sponsor
- Hoffmann-La Roche
Metastatic Melanoma
A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients
The purpose of this study is to test the combination of Ipilimumab and GM-CSF. Both ipilimumab and GM-CSF are intended to work with the body's own immune system to attack melanoma cells in the body.
- Trial name
- NCT02009397
- Testing
- Ipilimumab, GM-CSF
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Louisville
Infection by Streptococcus Group B
Safety and Immunogenicity of a Group B Streptococcus Vaccine in Non-pregnant Women 18-40 Years of Age.
Part A: The primary objective is to evaluate the safety and tolerability of a potential vaccine against Group B streptococcus. Part B: To evaluate the long term safety profile of the GBS-NN vaccine up to one year following the…
- Trial name
- MVX13211 (NCT02459262)
- Testing
- GBS-NN vaccine
- Where
- United Kingdom
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Minervax ApS
Vaccine Response Impaired
Vaccine Hyporesponse in Healthy Elderly Participants (MK-0000-131 AM2)
This study evaluated whether it is possible in healthy elderly participants to generate baseline biomarker-based prediction rules (PdR) for vaccine response (post baseline absolute serum antibody titer) using each of the protocol…
- Trial name
- NCT01119703
- Testing
- Tetanus & Diphtheria booster vaccine (Td), TwinrixTM [Hepatitis A Inactivated & Hepatitis B (Recombinant) Vaccine], Dukoral® Traveler's Diarrhea Vaccine (WC/rBS)
- Volunteers
- 174 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer
This phase II trial is studying how well rituximab works in preventing acute graft-versus-host disease (GVHD) in patients undergoing a donor stem cell transplant for hematologic cancer.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Nasal Type Extranodal NK/T-cell Lymphoma
- Trial name
- NCT01044745
- Testing
- rituximab, mycophenolate mofetil, tacrolimus
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Nebraska
Solid Tumor
Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors
The purpose of this study is to determine whether the combination of Ulocuplumab and Nivolumab is safe and effective in the treatment of pancreatic cancer and small cell lung cancer.
- Trial name
- CXCessoR4 (NCT02472977)
- Testing
- Ulocuplumab, Nivolumab
- Where
- 7 sites in United States, Finland
- Volunteers
- 61 people
- Sponsor
- Bristol-Myers Squibb
Primary Myelofibrosis (PMF), Post-Polycythaemia Vera
Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases
This study is being conducted to test study drug AZD1480 to see how it may work to treat myeloproliferative diseases. The main purpose of this study is to determine the safety and tolerability of AZD1480.
- Conditions
- Primary Myelofibrosis (PMF), Post-Polycythaemia Vera, Essential Thrombocythaemia Myelofibrosis
- Trial name
- NCT00910728
- Testing
- AZD1480
- Where
- 3 sites in United States, France
- Volunteers
- 65 people
- Sponsor
- AstraZeneca
Recurrent Prostate Cancer, Stage I Prostate Cancer
Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer
This phase II trial studies how well lapatinib ditosylate works in treating patients with a rising prostate-specific antigen (PSA), a protein made by the prostate gland, indicating that prostate cancer has come back after…
- Conditions
- Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
- Trial name
- NCT00103194
- Testing
- lapatinib ditosylate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- National Cancer Institute (NCI)
Adenomatous Polyp, Recurrent Colon Cancer
Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma
This randomized phase II trial is studying how well erlotinib hydrochloride works in treating patients with stage I-III colorectal cancer or adenoma.
- Conditions
- Adenomatous Polyp, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage I Colon Cancer
- Trial name
- NCT00754494
- Testing
- erlotinib hydrochloride, laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Hemophilia A
A Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 (PF-07055480) in Subjects With Severe Hemophilia A
The purpose of the study is to evaluate the safety, tolerability and time-course profile of FVIII activity after dosing with SB-525 (PF-07055480)
- Trial name
- NCT03061201
- Testing
- SB-525 (PF-07055480)
- Where
- 22 sites in United States
- Volunteers
- 13 people
- Sponsor
- Pfizer
Respiratory Distress Syndrome, Newborn
Aerosolized Surfactant in Neonatal RDS
Respiratory distress syndrome (RDS), caused by surfactant deficiency, is the leading cause of mortality and morbidity in preterm infants.
- Trial name
- AS-02 (NCT02294630)
- Testing
- Surfactant
- Where
- United States
- Volunteers
- 159 people
- Sponsor
- Sood, Beena G., MD, MS
Small Cell Lung Cancer
A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer
The purpose of this study is to assess the safety and efficacy of rovalpituzumab tesirine administered in combination with nivolumab or nivolumab and ipilimumab in participants with extensive-stage small cell lung cancer (SCLC).
- Trial name
- NCT03026166
- Testing
- Ipilimumab, Nivolumab, Rovalpituzumab tesirine
- Where
- 35 sites in United States, France and 3 more
- Volunteers
- 42 people
- Sponsor
- AbbVie
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.